KRAS and cancer: In KRAS-driven pancreatic cancer models, deletion of LKB1 enhanced the tumorigenicity and proliferation rate of cancer cells through enhanced serine biosynthesis and S-adenosyl-methionine (SAM), which supports DNA methylation (75).